Analysts Conflicted on These Healthcare Names: Alnylam Pharma (ALNY), Kindred Biosciences (KIN) and Proteon (PRTO)


Analysts have been eager to weigh in on the Healthcare sector with new ratings on Alnylam Pharma (ALNY), Kindred Biosciences (KIN) and Proteon (PRTO).

Alnylam Pharma (ALNY)

In a report released today, Alan Carr from Needham maintained a Buy rating on Alnylam Pharma, with a price target of $135. The company’s shares opened today at $76.05, close to its 52-week low of $71.85.

According to TipRanks.com, Carr is a 4-star analyst with an average return of 2.9% and a 40.3% success rate. Carr covers the Healthcare sector, focusing on stocks such as Biohaven Pharmaceutical Holding Co Ltd, ACADIA Pharmaceuticals Inc, and Rhythm Pharmaceuticals Inc.

Alnylam Pharma has an analyst consensus of Strong Buy, with a price target consensus of $145.08, representing a 90.8% upside. In a report released today, Piper Jaffray also reiterated a Buy rating on the stock with a $160 price target.

.

See today’s analyst top recommended stocks >>

Kindred Biosciences (KIN)

In a report released today, Brandon Folkes from Cantor Fitzgerald reiterated a Buy rating on Kindred Biosciences, with a price target of $25. The company’s shares opened today at $14.59, close to its 52-week high of $15.75.

Folkes noted:

“. Post 3Q18, we reiterate our Overweight rating and 12-month price target of $25. We believe KIN’s pipeline of novel animal health drugs will drive long-term shareholder value beyond levels currently reflected in the current stock price. As KIN advances its pipeline, investors should begin to appreciate the durability and peak revenue potential of the products the company brings to market. Kindred has one approved product, Mirataz, and expects the approval of Zimeta IV next year, with two approvals a year thereafter. In addition, we believe the company will continue to highlight new undisclosed pipeline products in 2019.”

According to TipRanks.com, Folkes is a 3-star analyst with an average return of 3.0% and a 51.9% success rate. Folkes covers the Healthcare sector, focusing on stocks such as Biohaven Pharmaceutical Holding Co Ltd, Opiant Pharmaceuticals Inc, and Eagle Pharmaceuticals Inc.

Currently, the analyst consensus on Kindred Biosciences is a Strong Buy with an average price target of $19, representing a 30.2% upside. In a report issued on October 31, H.C. Wainwright also maintained a Buy rating on the stock with a $16 price target.

.

Proteon (PRTO)

Cowen & Co. analyst Boris Peaker maintained a Hold rating on Proteon today. The company’s shares opened today at $1.66, close to its 52-week low of $1.50.

According to TipRanks.com, Peaker is a 4-star analyst with an average return of 7.2% and a 42.0% success rate. Peaker covers the Healthcare sector, focusing on stocks such as Corvus Pharmaceuticals Inc, Stemline Therapeutics Inc, and Mersana Therapeutics Inc.

Proteon has an analyst consensus of Moderate Buy, with a price target consensus of $4.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts